Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A 2-part Phase 2 Study to Assess the Efficacy, Safety, and Tolerability of SLS-002 (Intranasal Racemic Ketamine) Administered to Adults With Major Depressive Disorder at Imminent Risk of Suicide

Next Previous
Trial Profile

A 2-part Phase 2 Study to Assess the Efficacy, Safety, and Tolerability of SLS-002 (Intranasal Racemic Ketamine) Administered to Adults With Major Depressive Disorder at Imminent Risk of Suicide

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 29 Dec 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ketamine (Primary)
  • Indications Major depressive disorder; Suicidal ideation
  • Focus Proof of concept; Registrational; Therapeutic Use
  • Sponsors Seelos Therapeutics

Most Recent Events

  • 22 Dec 2023 According to a Seelos Therapeutics media release, the company completed End of Phase II meeting with the FDA on December 20th and will provide updates to stockholders once the FDA releases official minutes from the meeting.
  • 20 Sep 2023 Status changed to completed, according to Seelos Therapeutics media release.
  • 20 Sep 2023 According to Seelos Therapeutics media release, company expects to move forward with development of SLS-002 after the end of Phase II meeting with the FDA.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top